The combination of Yervoy and Opdivo was tested on mesothelioma and the overall survival was promising. The overall survival was 18.1 months versus 14.1 months for patients receiving just chemotherapy. This is the first time that a phase III trial had an improved survival with an immunotherapy combination in a[…]
Latest Immunotherapy Treatments
Genetically Modified T-Cells for the Treatment of Mesothelioma and Other Tumors
Genetically modified T cells are a promising treatment for those suffering from mesothelioma. There is only data from five patients, but the results so far look good. The Phase I part of the study is looking at the safety and efficacy of the treatment and is finding out what dosage[…]
A Combination of Immunotherapy Drugs Could Help Mesothelioma Patients
Mesothelioma is an incurable cancer of the mesothelium resulting from asbestos exposure. Many clinical trials have been found to help patients but there is still no cure. People primarily have pleural mesothelioma where the linings of the lungs have cancer, but it can also affect the lining of the abdomen[…]
Keytruda is Now Approved for Mesothelioma and Other Cancers
Keytruda is now approved for certain mesothelioma patients. The immunotherapy drug has been tested for mesothelioma before, but has not been approved for the treatment of it. The approval is for adult and pediatric cancers with unresectable disease and high mutational burden that have been treated and have no other[…]
Opdivo and Yervoy Work Together to Treat Pleural Mesothelioma
Mesothelioma is an aggressive cancer with very few treatment options. Patients have a low survival rate, but there is hope with clinical trials. If a clinical trial is found to be effective, patients could live longer and could eventually be cured. Opdivo and Yervoy are two immunotherapy drugs that are[…]
Nivolumab to Help Treat Mesothelioma
A new study found that the PD-L1 inhibitor nivolumab is effective in mesothelioma. It was tested on patients and showed that it could be a safe and effective treatment for those whose first line treatments have failed. Nivolumab is an immunotherapy drug that helps the immune system fight cancer cells.[…]
2019 Mesothelioma Treatments in Review
There have been many different advances in medicine benefitting mesothelioma patients, and over the course of 2019, different clinical trials have shown that there is still hope for them. One of the clinical trials in 2019 studied Nivolumab, also called Opdivo, as a first- and second-line treatment for mesothelioma. The[…]
New Clinical Trial Testing Effectiveness of Immunotherapy and Chemotherapy Before Surgery
Mesothelioma, the cancer of the linings of different organs, but primarily the lungs, has a poor prognosis and survival rate for those who are diagnosed. Since there is no cure, treatments helping to extend people’s lives need to be tested. Clinical trials help doctors find new ways to treat mesothelioma[…]
CAR T-Cell Therapy Could Soon be used on Mesothelioma Patients
An immunotherapy treatment that utilizes T cells to fight cancer may soon be covered by Medicare for mesothelioma patients. Immunotherapy is still an emerging set of cancer treatments that utilizes the patient’s own immune system to fight and kill cancer cells. The specific treatment that uses T cells is called[…]
Opdivo and MTG201 Together Could Potentially Treat Mesothelioma
Typical cancer treatments are hard on the body and are not always effective. When treating someone for cancer, chemotherapy is typically used, which kills cancer cells or stops them from growing or spreading. Chemotherapy can also kill healthy cells, which makes it hard on the body. Immunotherapy is another option,[…]